Form 8-K

8-K — Indivior Pharmaceuticals, Inc.

Accession: 0001104659-26-113883

Filed: 2026-10-06

Period: 2026-10-06

CIK: 0001625297

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Documents

8-K — tm2627060d1_8k.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2627060d1_8k.htm · Sequence: 1

false

0001625297

2026-10-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 6, 2026

INDIVIOR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its

charter)

Delaware

001-37835

41-2520873

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

10710 Midlothian Turnpike, Suite

125

North Chesterfield, VA

23235

(Address of principal executive offices)

(Zip Code)

804-379-1090

(Registrant’s telephone number, including

area code)

Not Applicable

(Former Name or Former Address, if Changed

Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.

below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common stock, $0.001 par value per share

INDV

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of

1934 (17 CFR 240.12b-2).

Emerging Growth Company ¨

If an emerging growth company, indicate

by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial

accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

As previously reported, on

August 1, 2026, Indivior Pharmaceuticals, Inc., a Delaware corporation (the “Indivior”), entered into an Agreement and Plan

of Merger (the “Merger Agreement”) with Supernus Pharmaceuticals, Inc., a Delaware corporation (“Supernus”) and

Artemis Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Indivior (“Merger Sub”). The Merger Agreement

provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Supernus

(the “Merger”), with Supernus continuing as the surviving company and a wholly owned subsidiary of Indivior following the

transaction. As a result of the Merger, Indivior will be renamed Supernus, Inc. (the “Combined Company”).

In connection with the Merger,

Indivior filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 28, 2026, and subsequently amended

prior to effectiveness, a Registration Statement on Form S-4 (File No. 333-298637) to register the shares of Indivior’s common

stock to be issued in connection with the Merger (as amended, the “Registration Statement”). The Registration Statement includes

a joint proxy statement of Indivior and Supernus (the “definitive joint proxy statement/prospectus”). The Registration Statement

was declared effective by the SEC on September 11, 2026, and the definitive joint proxy statement/prospectus was first mailed to the

stockholders of each of Indivior and Supernus. Indivior is filing this Current Report on Form 8-K (this “Supplement”) to

update and supplement the definitive joint proxy statement/prospectus.

Each of Indivior and Supernus

will hold a special meeting of its stockholders on October 15, 2026 in connection with the Merger, as further described in the definitive

joint proxy statement/prospectus.

Capitalized terms used but

not otherwise defined in this Supplement have the meanings given to them in the definitive joint proxy statement/prospectus. This Supplement

should be read in conjunction with the definitive joint proxy statement/prospectus, which should itself be read in its entirety. Except

as specifically supplemented by the information contained in this Supplement, all information set forth in the definitive joint proxy

statement/prospectus remains unchanged. To the extent that information in this Supplement differs from or updates information contained

in the definitive joint proxy statement/prospectus, the information in this Supplement is more current and supersedes the different or

inconsistent information contained in the definitive joint proxy statement/prospectus.

Background of the Supplemental Disclosures

Following the filing of the

definitive joint proxy statement/prospectus, Supernus received demand letters from purported Supernus stockholders (collectively, the

“Demand Letters”) and two complaints were filed by purported stockholders of Supernus in the Supreme Court of the State of

New York, County of New York (collectively, the “Complaints”). The Demand Letters and Complaints generally allege, among

other things, that the definitive joint proxy statement/prospectus contains certain disclosure deficiencies and/or incomplete information

regarding the Merger.

Supernus believes that the

claims asserted in the Demand Letters and Complaints are without merit and that no supplemental disclosure to the definitive joint proxy

statement/prospectus is or was required under any applicable law, rule or regulation. Supernus denies that it has violated any law or

breached any duty to its stockholders, and denies all of the allegations in the Demand Letters and Complaints. However, solely to eliminate

the burden, expense and uncertainty of litigation, to moot disclosure claims asserted in the Demand Letters and Complaints, and to avoid

the risk that the Demand Letters or Complaints may delay or otherwise adversely affect the Merger, and without admitting any liability

or wrongdoing, Supernus and Indivior have determined to voluntarily supplement the definitive joint proxy statement/prospectus with the

disclosures set forth below (the “Supplemental Disclosures”). Nothing in this Supplement shall be deemed an admission of

the legal necessity or materiality under any applicable law of any of the Supplemental Disclosures. To the contrary, Supernus and Indivior

specifically deny that any additional disclosure is or was required.

SUPPLEMENTAL DISCLOSURES TO JOINT PROXY STATEMENT/PROSPECTUS

The following Supplemental

Disclosures should be read together with the joint proxy statement/prospectus, which should be read in its entirety. To the extent the

information set forth herein differs from or updates information contained in the joint proxy statement/prospectus, the information herein

supersedes or supplements that information. All page references are to pages in the joint proxy statement/prospectus, and capitalized

terms used but not defined herein have the meanings given to them in the joint proxy statement/prospectus. New text is indicated in bold,

underlined text and, where applicable, deleted text is indicated in strikethrough text.

1. The

disclosure under the heading “The Merger—Opinion of Supernus's Financial Advisor—Opinion

of Cantor Fitzgerald—Selected Companies Analysis—Supernus,” beginning on

page 89 of the joint proxy statement/prospectus, is amended and supplemented by amending

and restating the second sentence of the fourth paragraph thereof as follows.

Cantor

then adjusted for Supernus’s estimated cash and debt of approximately $372 million and debt of $0, in

each case, as provided by Supernus’s management and approved for Cantor’s use by Supernus’s management, and

divided by the number a range of fully diluted shares of Supernus Shares of approximately 60.3 million

to 61.4 million based on 2027E Revenue and approximately 60.3 million to 61.5 million based on 2028E Revenue, as provided by Supernus’s

management and approved for Cantor’s use by Supernus’s management (determined using the treasury stock method) as

of July 28, 2026.

The

disclosure under the heading “The Merger—Opinion of Supernus's Financial Advisor—Opinion of Cantor Fitzgerald—Selected

Companies Analysis—Indivior,” beginning on page 89 of the joint proxy statement/prospectus, is amended and supplemented by

amending and restating the second sentence of the fourth paragraph thereof as follows.

Cantor

then adjusted for Indivior’s estimated cash and debt of approximately $249 million and debt of approximately

$500 million, in each case, as provided by Supernus’s management and approved for Cantor’s use by Supernus’s management,

further reduced the resulting implied equity value by the $1 billion aggregate amount of the Special Dividend and divided by the

number a range of fully diluted Indivior Shares of approximately 139.2 million to 139.3 million based on

2027E Revenue and approximately 124.0 million to approximately 139.3 million based on 2028E Revenue, as provided by Supernus’s

management and approved for Cantor’s use by Supernus’s management (determined using the treasury stock method) as

of July 28, 2026.

2. The

disclosure in the section entitled “The Merger—Opinion of Supernus's Financial

Advisor—Opinion of Cantor Fitzgerald—Discounted Cash Flow Analyses—Discounted

Cash Flow Analysis—Supernus,” beginning on page 90 of the joint proxy statement/prospectus,

is amended and supplemented by amending and restating the second and third paragraphs thereof

as follows:

In performing this analysis, Cantor

calculated a range of equity values for Supernus Shares by (a) discounting to June 30, 2026, using discount rates ranging from

9.5% to 11.5% (reflecting Supernus’s estimated weighted average cost of capital, derived using the Capital Asset Pricing Model

and a size premium) and the mid-year convention, (i) the forecasted risk-adjusted, after-tax unlevered free cash flows of Supernus

over the forecast period and (ii) an implied terminal value of Supernus, calculated assuming that Supernus’s after-tax unlevered

free cash flow would grow or decline in perpetuity after December 31, 2040 at rates ranging from negative 10.0% to positive 3.0%,

reflecting Supernus’s management guidance regarding product and indication loss of exclusivities, continued pipeline growth outlook,

and the impact from potential competition in the indications, and (b) adjusting for Supernus’s estimated cash and

debt of approximately $372 million and debt of $0, in each case, as provided by Supernus’s management and approved

for Cantor’s use by Supernus’s management, and the estimated present value of certain remaining net operating losses

and other tax attributes after 2040.

Cantor then divided the resulting equity

values by the applicable number range of fully diluted shares of Supernus Shares of approximately

61.0 million to 61.7 million, as provided by Supernus’s management and approved for Cantor’s use by Supernus’s management

(determined using the treasury stock method) as of July 28, 2026. This analysis indicated an approximate implied per share equity

value reference range for Supernus Shares of $50.55 to $59.50.

3. The

disclosure in the section entitled “The Merger—Opinion of Supernus's Financial

Advisor—Opinion of Cantor Fitzgerald— Discounted Cash Flow Analyses—Discounted

Cash Flow Analysis—Indivior,” beginning on page 91 of the joint proxy statement/prospectus,

is amended and supplemented by amending and restating the second and third paragraphs thereof

as follows:

In performing this analysis, Cantor

calculated a range of equity values for Indivior Shares by (a) discounting to June 30, 2026, using discount rates ranging from

8.0% to 10.0% (reflecting Indivior’s estimated weighted average cost of capital, derived using the Capital Asset Pricing Model

and a size premium) and the mid-year convention, (i) the forecasted after-tax unlevered free cash flows of Indivior over the forecast

period and (ii) an implied terminal value of Indivior, calculated assuming that Indivior’s after-tax unlevered free cash flow

would grow or decline in perpetuity after December 31, 2040 at rates ranging from negative 10.0% to positive 3.0%, reflecting Supernus’s

management guidance regarding product and indication loss of exclusivity, continued commercial growth outlook, and the impact from potential

competition in the indication, and (b) adjusting for Indivior’s estimated cash and debt of approximately

$249 million and debt of approximately $500 million, in each case, as provided by Supernus’s management and approved for Cantor’s

use by Supernus’s management, and the $1 billion Special Dividend.

Cantor then divided the resulting equity

values by the applicable number range of fully diluted Indivior Shares of approximately 124.0 million

to 139.3 million, as provided by Supernus’s management and approved for Cantor’s use by Supernus’s management,

determined using the treasury stock method as of July 28, 2026. This analysis indicated an approximate dividend-adjusted implied

per share equity value reference range for Indivior Shares of $24.20 to $43.90.

4. The

disclosure in the section entitled “The Merger—Opinion of Supernus's Financial

Advisor—Opinion of Cantor Fitzgerald—Illustrative Contribution Analysis,”

beginning on page 91 of the joint proxy statement/prospectus, is amended and supplemented

by amending and restating the third sentence of the first paragraph thereof as follows:

Cantor then adjusted for each company’s

estimated cash and debt of approximately $372 million for Supernus and of approximately $249 million for Indivior

and debt of $0 million for Supernus and of approximately $500 million for Indivior, in each case, as provided by Supernus’s

management and approved for Cantor’s use by Supernus’s management, to calculate the implied equity value for each

company, and further divided by the number of fully diluted shares of Supernus Shares of approximately 60.8 million and of Indivior

Shares of approximately 124.0 million, as provided by Supernus’s management and approved for Cantor’s use by Supernus’s

management (determined using the treasury stock method), in each case as of July 28, 2026, to calculate the

implied equity value per share for each company.

5. The

disclosure under the heading “The Merger—Opinion of Supernus's Financial Advisor—Opinion

of Cantor Fitzgerald—Selected Precedent Transactions Analysis—Supernus,”

beginning on page 92 of the joint proxy statement/prospectus, is amended and supplemented

by amending and restating the second sentence of the third paragraph thereof as follows:

Cantor

then adjusted for Supernus’s estimated cash and debt of approximately $372 million and debt of $0, in

each case, as provided by Supernus’s management and approved for Cantor’s use by Supernus’s management, and

divided by the applicable number range of fully diluted Supernus Shares of approximately 61.1 million

to 62.1 million, as provided by Supernus’s management and approved for Cantor’s use by Supernus’s management

(determined using the treasury stock method) as of July 28, 2026.

6. The

disclosure under the heading “The Merger—Opinion of Supernus's Financial Advisor—Opinion

of Cantor Fitzgerald—Selected Precedent Transactions Analysis—Indivior,”

beginning on page 92 of the joint proxy statement/prospectus, is amended and supplemented

by amending and restating the second sentence of the second paragraph thereof as follows:

Cantor

then adjusted for Indivior’s estimated cash and debt of approximately $249 million and debt of approximately

$500 million, in each case, as provided by Supernus’s management and approved for Cantor’s use by Supernus’s management,

further reduced the resulting implied equity value by the $1 billion Special Dividend and divided by the applicable numberrange

of fully diluted Indivior Shares of approximately 124.0 million to 139.3 million, as provided by Supernus’s management and

approved for Cantor’s use by Supernus’s management (determined using the treasury stock method) as of July 28,

2026.

Important Additional Information and Where

to Find It

In connection with the proposed transaction,

Indivior filed with the SEC on September 11, 2026, a document that serves as a prospectus of Indivior and a definitive joint proxy statement

of Indivior and Supernus (the “joint proxy statement/prospectus”). On September 11, 2026, Supernus filed with the SEC the

definitive joint proxy statement/prospectus relating to the Merger and the Supernus Special Meeting. Each party has filed other relevant

documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS

AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The definitive

joint proxy statement/prospectus has been sent to Indivior’s stockholders and Supernus’ stockholders. Investors and securityholders

may obtain a free copy of the joint proxy statement/prospectus and other relevant documents filed by Indivior and Supernus with the SEC

at the SEC’s website at www.sec.gov. Copies of the documents filed by Indivior with the SEC are available free of charge

on Indivior’s website at www.indivior.com or by contacting Indivior’s Investor Relations at InvestorRelations@indivior.com.

Copies of the documents filed by Supernus with the SEC are available free of charge on Supernus’ website at www.supernus.com.

No Offer or Solicitation

This supplement and the information contained

herein is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy or exchange

any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such

offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This supplement does not constitute a prospectus or prospectus equivalent document. No offer of securities shall be made except by means

of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

Indivior and Supernus and their respective directors,

executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect

of the proposed transaction. Information about directors and executive officers of Indivior is available in the Indivior proxy statement

for its 2026 Annual Meeting, which was filed with the SEC on March 27, 2026. Information about directors and executive officers of Supernus

is available in the Supernus proxy statement for its 2026 Annual Meeting, which was filed with the SEC on April 30, 2026. Other information

regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or

otherwise, are contained in the joint proxy statement/prospectus and other relevant materials filed with the SEC regarding the proposed

transaction. Investors should read the joint proxy statement/prospectus carefully before making any voting or investment decisions. Investors

may obtain free copies of these documents from Indivior and Supernus as indicated above.

Forward-Looking Statements

This supplement contains forward-looking statements

within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. From time to time,

oral or written forward-looking statements may also be included in other information released to the public. These forward-looking statements

are intended to provide Supernus’s and Indivior’s respective management’s current expectations or plans for our future

operating and financial performance, based on assumptions currently believed to be valid. Words such as “anticipate,” “believe,”

“estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,”

“would,” “could,” “should,” and similar expressions are intended to identify forward-looking statements,

although not all forward-looking statements contain these words. All forward-looking statements involve risks, uncertainties and other

factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. These statements,

including statements regarding the proposed merger of equals of Supernus and Indivior, the expected timing of the closing, and the anticipated

benefits and prospects of the combined company, are based on management’s current expectations and are subject to risks and uncertainties

that could cause actual results to differ materially, including, among others: the risk that the proposed merger may not be completed

in a timely manner or at all; the failure to obtain the required approvals of Supernus' or Indivior’s stockholders; the failure

or delay in obtaining required regulatory approvals, or the imposition of conditions in connection therewith; the failure to satisfy

the other conditions to closing; the possibility that a competing or superior acquisition proposal is made; the fact that the exchange

ratio is fixed and will not be adjusted for changes in the market price of Supernus or Indivior shares; the effect of the announcement,

pendency or completion of the transaction on the market price of Supernus and Indivior shares; the effect of the additional indebtedness

incurred to fund the Special Dividend on the combined company; the effects of business disruption resulting from the announcement or

pendency of the transaction; the diversion of management’s attention and resources from ongoing business operations; the effect

of the transaction on the parties’ ability to retain and hire key personnel and to maintain relationships with customers, suppliers

and other business partners; restrictions during the pendency of the transaction that may limit the parties’ ability to pursue

business opportunities or strategic transactions; the risk that the anticipated benefits, synergies and cost savings may not be realized

within the expected timeframe or at all; the difficulties and costs of integrating the two businesses; significant transaction costs

and/or unknown or inestimable liabilities; the risk that the merger does not qualify for its intended treatment as a tax-free reorganization;

the occurrence of any event that could give rise to termination of the merger agreement, including in circumstances requiring payment

of a termination fee; the risk of stockholder litigation in connection with the transaction; the impact of macroeconomic and market conditions,

including economic downturns, international conflict, trade disputes and tariffs; and the other risks identified in Supernus’ and

Indivior’s filings with the SEC and in the joint proxy statement/prospectus. There can be no assurance that the proposed merger

will in fact be consummated in the manner described or at all. These forward-looking statements speak only as of the date of this supplement

and neither Supernus nor Indivior undertakes any obligation to update any forward-looking statement, except as required by applicable

law.

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INDIVIOR PHARMACEUTICALS, INC.

Date:

October 6, 2026

By:

/s/ Ryan Preblick

Name:

Ryan Preblick

Title:

Chief Financial Officer

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.3

Cover

Oct. 06, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 06, 2026

Entity File Number

001-37835

Entity Registrant Name

INDIVIOR PHARMACEUTICALS, INC.

Entity Central Index Key

0001625297

Entity Tax Identification Number

41-2520873

Entity Incorporation, State or Country Code

Entity Address, Address Line One

10710 Midlothian Turnpike

Entity Address, Address Line Two

Suite

125

Entity Address, City or Town

North Chesterfield

Entity Address, State or Province

Entity Address, Postal Zip Code

23235

City Area Code

804

Local Phone Number

379-1090

Written Communications

true

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.001 par value per share

Trading Symbol

INDV

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration